Loading clinical trials...

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants | Clinical Trials | Clareo Health

TERMINATEDPhase 3

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Efficacy, Safety, Reactogenicity, and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Japanese Adults Aged 60 Years and Older, and Safety, Reactogenicity, and Immunogenicity of the Vaccine in Japanese Adults Aged 20 to 59 Years at High-risk of RSV Disease

NCT05242432•Janssen Pharmaceutical K.K.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Respiratory Syncytial Virus Prevention

Interventions

Ad26/protein preF RSV Vaccine

Placebo

Locations

30

Japan

Locations (30)

Shohokai Toda Internal Medicine and Neurology Clinic

Akashi-shi, Japan

Doujin Memorial Meiwa Hospital

Chiyoda-ku, Japan

Fukuwa Clinic

Chūō, Japan

Tokyo-Eki Center-Building Clinic

Chūōku, Japan

Tokyo Asbo Clinic

Chūōku, Japan

Tenjin Sogo Clinic

Fukuoka, Japan

Key Dates

Start Date

April 1, 2022

Primary Completion Date

March 20, 2023

Completion Date

March 20, 2023

Last Updated

May 23, 2025

Related Studies

First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory

NCT07177508

Respiratory Syncytial Viral (RSV) InfectionRespiratory Syncytial Virus Hospitalizations+1 more

COMPLETEDPhase 3

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

NCT05083585

Respiratory Syncytial Virus Prevention

Sponsors

Lead Sponsor

Janssen Pharmaceutical K.K.

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions